Business Context and Reporting Period
This Form 8-K filing by SELLAS Life Sciences Group, Inc. (Delaware) was submitted on July 23, 2018, reporting events occurring on July 18, 2018. The filing addresses Item 5.02 regarding the departure of a director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
The material change reported is the resignation of Fabio López, a Class II director of the Company. Mr. López notified the Company of his decision on July 18, 2018, with the resignation effective July 27, 2018. The Company explicitly stated that the resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies beyond the director departure. No unusual items were reported.
Investor Verification Checklist
- Verify the effective date of Fabio López's resignation (July 27, 2018).
- Confirm the composition of the Board of Directors following this departure.
- Review subsequent filings to determine if a replacement director was appointed.